American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 421-432, September 2007

Should Hemodialysis Patients With Atrial Fibrillation Undergo Systemic Anticoagulation? A Cost-Utility Analysis

  • Robert R. Quinn, MD, FRCPC

      Affiliations

    • Department of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, Toronto, Canada
    • Corresponding Author InformationAddress correspondence to Robert R. Quinn, MD, FRCPC, Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Rm A239, Toronto, Ontario, Canada M4N 3M5.
  • ,
  • David M.J. Naimark, MD, MSc, FRCPC

      Affiliations

    • Department of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, Toronto, Canada
    • Medicine and Health Policy Management and Evaluation, University of Toronto, Toronto, Canada
  • ,
  • Matthew J. Oliver, MD, MHS, FRCPC

      Affiliations

    • Chronic Dialysis, Sunnybrook Health Sciences Centre, Toronto, Canada
  • ,
  • Ahmed M. Bayoumi, MD, MSc, FRCPC

      Affiliations

    • Medicine and Health Policy Management and Evaluation, University of Toronto, Toronto, Canada
    • Centre for Research on Inner City Health, The Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael’s Hospital, University of Toronto, Toronto, Canada.

Received 19 December 2006; accepted 23 May 2007. published online 10 August 2007.

Background

Approximately 14% of hemodialysis patients have atrial fibrillation. Hemodialysis patients with atrial fibrillation appear to be at increased risk of both thromboembolic complications and bleeding. Furthermore, there is uncertainty regarding the efficacy of warfarin or acetylsalicylic acid (ASA) therapy for preventing strokes in this subgroup because they were excluded from relevant trials.

Study Design

We performed a cost-utility analysis. Probabilistic sensitivity analysis was used to incorporate parameter uncertainty into the model. Expected value of perfect information and scenario analyses were performed to identify the important drivers of the decision and focus future research.

Setting & Population

Base case was a 60-year-old male hemodialysis patient in the United States.

Model, Perspective, & Time Frame

A Markov Monte Carlo microsimulation model was constructed from the perspective of the health care payer, and patients were followed up during their lifetime.

Intervention

We compared 3 alternative treatment strategies for permanent atrial fibrillation in hemodialysis patients: warfarin, ASA, or no treatment.

Outcomes

Quality-adjusted survival and cost.

Results

ASA and warfarin both prolonged survival compared with no treatment (0.06 and 0.15 quality-adjusted life-years [QALYs], respectively). ASA was associated with an incremental cost-effectiveness ratio of $82,100/QALY. Warfarin provided additional benefits at a cost of $88,400 for each QALY gained relative to ASA. At a threshold of $100,000/QALY, the probabilities that no treatment, warfarin, and ASA were the most efficient therapy were 20%, 58%, and 23%, respectively.

Limitations

Parameterization data and costs were taken from US studies and may not be generalizable to other countries. Peritoneal dialysis patients were not included in the analysis.

Conclusions

The high future cost of hemodialysis constrains incremental cost-effectiveness ratios to values greater than commonly cited thresholds ($50,000/QALY). Based on available evidence, warfarin appears to be the optimal therapy to prevent thromboembolic stroke in hemodialysis patients with atrial fibrillation. Additional study is required to determine the efficacy of warfarin and risk of bleeding complications in this population so that patients can make a more informed choice.

Index Words: Atrial fibrillation, hemodialysis, cost-effectiveness, warfarin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2007.05.019 on August 9, 2007.

PII: S0272-6386(07)00844-X

doi:10.1053/j.ajkd.2007.05.019

Refers to article:

  • Anticoagulation for Chronic Atrial Fibrillation in Hemodialysis Patients: Which Fruit From the Decision Tree?

    Kevin C. Abbott, Robert T. Neff, Erin M. Bohen, Rajeev Narayan
    American Journal of Kidney Diseases September 2007 (Vol. 50, Issue 3, Pages 345-348)

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 421-432, September 2007